Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;29(6):628-32.
doi: 10.1097/MOG.0b013e328365d326.

Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs

Mark J Koenigsknecht  1 , Vincent B Young
Affiliations
Review

Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs

Mark J Koenigsknecht et al. Curr Opin Gastroenterol. 2013 Nov.

Abstract

Purpose of review: The use of faecal microbiota transplantation (FMT) as treatment for recurrent Clostridium difficile infection (CDI) has increased rapidly over the past few years. In this review, we highlight clinical studies of FMT for treatment of recurrent CDI and discuss the safety, standardization and future of this treatment option. The major risk factor for CDI is prior antibiotic use, which results in an altered state of the gut microbiota characterized by decreased microbial diversity. This altered gut microbiota increases the patient's susceptibility to CDI. In patients with recurrent CDI, the microbiota remains in a state with decreased diversity, and FMT from a healthy individual restores the gut microbiota and subsequently colonization resistance against the pathogen.

Recent findings: Recent studies have shown the success rate for FMT as treatment for recurrent CDI being greater than 90%. Standardized, frozen preparations of faeces can be used, which increases the availability of faeces for FMT and decreases the cost of screening individual donors. In addition, there have been recent advances in identifying a defined microbial community isolated from faeces that can restore colonization resistance against C. difficile.

Summary: The use of FMT is a successful treatment for recurrent CDI when primary treatment options have failed. However, more work needs to define potential long-term consequences of this treatment and understand how specific members of the gut microbiota can restore colonization resistance against C. difficile.

PubMed Disclaimer

References

    1. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998 May;41(Suppl C):21–27. PubMed PMID: 9630371. Epub 1998/06/18. eng. - PubMed
    1. Rousseau C, Levenez F, Fouqueray C, Dore J, Collignon A, Lepage P. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol. 2011 Mar;49(3):858–865. PubMed PMID: 21177896. Pubmed Central PMCID: 3067754. Epub 2010/12/24. eng. - PMC - PubMed
    1. van der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-v. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg (Lond) 1971 Sep;69(3):405–411. PubMed PMID: 4999450. Pubmed Central PMCID: 2130899. Epub 1971/09/01. eng. - PMC - PubMed
    1. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008 Dec;135(6):1984–1992. PubMed PMID: 18848941. Epub 2008/10/14. eng. - PubMed
    1. Voelker R. Increased Clostridium difficile virulence demands new treatment approach. Jama. 2010 May 26;303(20):2017–2019. PubMed PMID: 20501917. Epub 2010/05/27. eng. - PubMed

Publication types

MeSH terms